The Funding Is Real. The Talent Isn’t.
By nearly every metric, China’s biopharma industry has turned a corner. Drug out-licensing hit $135.6 billion across 157 deals in 2025 — a 2.5X jump year-on-year, according to industry data published by Faxiangongchang. BeiGene posted its first GAAP annual profit. NMPA approved a record 120 new drugs, more than half from domestic developers.
Then came the July headline that no one in the industry wanted to read.
A pediatric patient died in a gene-editing trial in China. Bloomberg reported on July 24 that the incident drew immediate scrutiny to the country’s fast-moving cell and gene therapy sector. In June, just weeks before, regulators had tightened clinical trial rules for advanced therapies — restricting them to designated hospitals and banning patient fees tied to research.
The regulatory tightening did not slow dealmaking. But it exposed a deeper weakness: China has too few experienced clinical-stage executives to manage the pipeline. In an industry where cross-border partnerships now drive more than half of late-stage development revenue, the talent gap becomes a bottleneck that no licensing agreement can fix.
A Structural Talent Mismatch
The math is simple on paper. The supply is not.
China’s biopharma industry now employs roughly 630,000 R&D and clinical professionals, based on Zhaopin’s Q1 2026 salary database spanning more than 560,000 valid job postings. But the number of executives with hands-on global Phase 2 and Phase 3 experience — the kind required to lead an out-licensed asset through FDA or EMA review — remains thin.
“Rolling out a global Phase 3 program from a Shanghai headquarters is a different skill set from managing a clinical trial in China alone,” observed a senior consultant at SunTzu Recruitment who specializes in life sciences leadership searches. “The candidate pool for a Chief Medical Officer with both NMPA and FDA submission experience is maybe a few dozen names worldwide — and most of them are already in senior roles at international pharma companies.”
A recent search conducted by SunTzu Recruitment for a Shanghai-based CMO at a publicly listed biotech took nine months to close. The starting offer exceeded ¥3 million in total compensation — and the first two candidates declined because they wanted board-level authority, not just trial oversight. The third candidate, a returnee with 15 years of experience at Novartis and Bristol Myers Squibb, accepted only after the client agreed to restructure the role to include a direct line to the board.
The Returnee Pipeline Is Slowing
For a decade, China’s biotech boom was powered by overseas Chinese scientists returning from the U.S. and Europe. That pipeline is narrowing.
Visa uncertainty, geopolitical friction, and a cooling venture market abroad have reduced the flow. Meanwhile, multinational pharma companies have been cutting China-based R&D headcount — shrinking the very pool that local biotechs relied on for experienced clinical leadership.
That leaves domestic biotechs competing for a smaller group of candidates. The result: salary inflation that alarms even seasoned board members. Chief Medical Officers now command ¥1.8 million to ¥3 million annually, according to Page Executive’s 2026 China compensation survey. Chief Scientific Officers sit at a similar range. And signing bonuses — once rare in Chinese biotech — have become standard for senior clinical roles.
A partner at SunTzu Recruitment described one recent search as “the hardest mandate we have run this year.” The client was a mid-stage oncology biotech with a promising bispecific antibody. Twenty candidates were contacted. Eleven agreed to an initial conversation. Three made it to the final round. None accepted the first offer.
“You cannot ‘buy’ a CMO the way you buy a CTO,” the partner said. “A clinical development leader needs to believe in the science, trust the board, and be willing to live with the regulatory risk. That is a different kind of scarcity.”
Regulation Tightens, Stakes Rise
The June regulatory overhaul adds a new dimension to the talent crunch. Under the new rules, cell and gene therapy trials must be conducted at approved hospitals with specialized oversight capacity. Principal investigators with the right credentials are already stretched across multiple programs.
To be fair, tighter regulation may help in the long run. Clearer guardrails could attract more international partners and make Chinese clinical data more acceptable to Western regulators. But in the short term, it raises the compliance bar — and the compliance burden lands on the same thin layer of experienced clinical executives.
SunTzu Recruitment’s life sciences team has begun incorporating regulatory scenario planning into every C-suite search for biotech clients. A candidate who has navigated an FDA clinical hold is now worth a premium. One who has done it in both the U.S. and China is rare enough that clients are willing to relocate them to Shanghai or Suzhou at any cost.
The $138 billion out-licensing wave is not a one-quarter anomaly. It reflects genuine maturation in China’s drug discovery capability. But for every deal celebrated, there is a clinical program waiting for its leader.
The talent bottleneck will not resolve through salary alone. It requires building a layer of mid-career clinical executives who have lived through a full development cycle — and that takes time. According to SunTzu Recruitment’s practice lead, biotech boards are increasingly asking for talent pipeline assessments before committing to new programs. The choice is becoming clear: either invest in executive development now, or watch promising pipelines stall for lack of someone to run them.
Comments are closed